Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 15, 2020 - Issue
Submit an article Journal homepage
110
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Effect of Inhaled Corticosteroid Withdrawal on Chronic Obstructive Pulmonary Disease Exacerbations in Patients Taking Triple Therapy at Baseline

Gary T Ferguson1 Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, USACorrespondence[email protected]
,
Asif Shaikh2 Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USAORCID Iconhttps://orcid.org/0000-0002-5116-9338
ORCID Icon,
Kay Tetzlaff3 Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany
,
Achim Mueller3 Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, GermanyORCID Iconhttps://orcid.org/0000-0002-4468-186X
ORCID Icon,
Helgo Magnussen4 Pulmonary Research Institute at Lung Clinic Grosshansdorf, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Germany
&
Henrik Watz4 Pulmonary Research Institute at Lung Clinic Grosshansdorf, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Germany
Pages 2879-2888 | Published online: 11 Nov 2020

References

  • GOLD. Global initiative for chronic obstructive lung disease. 2020 Available from: https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf. Accessed 1113, 2019.
  • Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2019 Available from: https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf. Accessed 1113, 2019.
  • BarnesPJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2008;8(3):183–192. doi:10.1038/nri225418274560
  • BarnesPJ. Inhaled corticosteroids in COPD: a controversy. Respiration. 2010;80(2):89–95. doi:10.1159/00031541620501985
  • PriceD, YawnB, BrusselleG, RossiA. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J. 2013;22(1):92–100. doi:10.4104/pcrj.2012.0009223135217
  • ChalmersJD, TebbothA, GayleA, TernouthA, RamscarN. Determinants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice. NPJ Prim Care Respir Med. 2017;27(1):43. doi:10.1038/s41533-017-0040-z28663549
  • FitchK, IwasakiK, PyensonB, PlauschinatC, ZhangJ. Variation in adherence with global initiative for chronic obstructive lung disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis. Curr Med Res Opin. 2011;27(7):1425–1429. doi:10.1185/03007995.2011.58323021599554
  • BrusselleG, PriceD, Gruffydd-JonesK, et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis. 2015;10:2207–2217. doi:10.2147/COPD.S9169426527869
  • MagnussenH, DisseB, Rodriguez-RoisinR, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285–1294. doi:10.1056/NEJMoa140715425196117
  • ChapmanKR, HurstJR, FrentSM, et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med. 2018;198(3):329–339. doi:10.1164/rccm.201803-0405OC29779416
  • MagnussenH, WatzH, KirstenA, et al. Stepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationale. Respir Med. 2014;108(4):593–599. doi:10.1016/j.rmed.2014.01.00224477080
  • VogelmeierC, WorthH, BuhlR, et al. “Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD. Int J Chron Obstruct Pulmon Dis. 2017;12:487–494. doi:10.2147/COPD.S12561628203072
  • van der ValkP, MonninkhofE, van der PalenJ, ZielhuisG, van HerwaardenC. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med. 2002;166(10):1358–1363. doi:10.1164/rccm.200206-512OC12406823
  • WoutersEF, PostmaDS, FokkensB, et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax. 2005;60(6):480–487. doi:10.1136/thx.2004.03428015923248
  • KunzLIZ, PostmaDS, KloosterK, et al. Relapse in FEV1 decline after steroid withdrawal in COPD. Chest. 2015;148(2):389–396. doi:10.1378/chest.14-309125836351
  • NadeemNJ, TaylorSJ, EldridgeSM. Withdrawal of inhaled corticosteroids in individuals with COPD – a systematic review and comment on trial methodology. Respir Res. 2011;12:107. doi:10.1186/1465-9921-12-10721838890
  • CalzettaL, MateraMG, BraidoF, et al. Withdrawal of inhaled corticosteroids in COPD: a meta-analysis. Pulm Pharmacol Ther. 2017;45:148–158. doi:10.1016/j.pupt.2017.06.00228606478
  • WatzH, TetzlaffK, WoutersEF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4(5):390–398. doi:10.1016/S2213-2600(16)00100-427066739
  • CalverleyPMA, TetzlaffK, VogelmeierC, et al. Eosinophilia, frequent exacerbations, and steroid response in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(9):1219–1221. doi:10.1164/rccm.201612-2525LE28306321
  • SinghS, LokeYK. An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2010;5:189–195. doi:10.2147/COPD.S694220714372

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.